# Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment

> **NCT02317783** · PHASE2 · TERMINATED · sponsor: **University of Utah** · enrollment: 15 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** [18F]Flutemetamol
- **DRUG:** [18F]fluoro-2-deoxy-D-glucose (FDG)
- **DIAGNOSTIC_TEST:** Functional Magnetic Resonance Imaging (fMRI)

## Key facts

- **NCT ID:** NCT02317783
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-31
- **Primary completion:** 2019-09-24
- **Final completion:** 2019-09-24
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Enrollment challenges
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02317783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02317783, "Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02317783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*